INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2021 |
Sep. 30, 2020 |
Sep. 30, 2021 |
Sep. 30, 2020 |
|
| Operating expenses: | ||||
| Research and development, net (Note 8) | $ 3,618 | $ 1,867 | $ 11,558 | $ 13,509 |
| General and administrative | 1,659 | 2,618 | 6,769 | 6,684 |
| Operating loss | (5,277) | (4,485) | (18,327) | (20,193) |
| Financial expenses (income), net | 59 | 3 | (60) | (197) |
| Net loss | $ (5,336) | $ (4,488) | $ (18,267) | $ (19,996) |
| Basic net loss per share from continuing operations | $ (0.15) | $ (0.14) | $ (0.51) | $ (0.70) |
| Diluted net loss per share from continuing operations | $ (0.15) | $ (0.14) | $ (0.51) | $ (0.70) |
| Weighted average number of shares outstanding used in computing basic net loss per share | 36,304,878 | 31,154,101 | 36,140,130 | 28,695,540 |
| Weighted average number of shares outstanding used in computing diluted net loss per share | 36,304,878 | 31,154,101 | 36,140,130 | 28,695,540 |